GT-02287, an oral therapy being developed by Gain Therapeutics, was associated with improvements in motor function over three months in people with Parkinson’s disease, including participants both with and without GBA1 mutations. The findings come from an open-label Phase 1b trial (NCT06732180), which also showed lower levels…
News
Neuralight said a newly completed study showed its machine learning-based system monitoring eye movements via webcam is more sensitive than traditional tests used for tracking Parkinson’s disease progression. “For the first time, a biomarker has outperformed the neurological gold standard in tracking Parkinson’s disease over time, unlocking a new…
Two proteins found on the surface of dopaminergic neurons, the nerve cells that are lost in Parkinson’s disease, may play a crucial role in the spread of toxic alpha-synuclein clumps throughout the brain, and blocking them could slow or halt disease progression. That’s according to a study from Yale…
A new high-tech imaging tool that can “see” the toxic protein clumps thought responsible for Parkinson’s disease is heading into clinical trials to help determine if an experimental therapy can slow the disease. Synusight Biotech has licensed its specialized positron emission tomography (PET) tracer ¹⁸F-FD4 to Abli Therapeutics…
A new collaboration aims to accelerate the development of large-molecule therapeutics capable of entering the brain to treat neurological conditions, starting with Parkinson’s disease and Alzheimer’s disease. The effort, from Mercury Bio and Meta-Flux, will combine Mercury’s yeast extracellular vesicle (yEV) technology, designed to deliver therapeutic molecules into…
A new study will investigate the long-term safety and effects of the experimental treatment buntanetap in people with Parkinson’s disease, according to Annovis Bio, the therapy’s developer. The open-label extension (OLE) study (NCT07284784) is expected to enroll about 500 adults with Parkinson’s disease, ages 40 to 85,…
Zambon Biotech has dosed the first patient in its clinical trial testing Crexont (IPX203) — an extended-release formulation of carbidopa/levodopa (CD/LD) that aims to ease so-called off episodes — among people with advanced Parkinson’s disease. With several locations now open in Italy, Poland, and Spain, the Phase…
Throughout 2025, the team at Parkinson’s News Today has reported on the latest research updates and advances in care related to Parkinson’s disease. Below is a list of the top 10 most-read articles we published this year. We look forward to continuing to serve as a source of news…
Aerobic exercise triggers a surge of dopamine in the brain that can significantly improve movement and coordination during the aging process, a new study in mice suggests. By providing “neurochemical evidence” for the benefits of staying active, researchers found that regular physical activity can help offset the natural decline of…
GT-02287, an oral therapy being developed by Gain Therapeutics, can increase glucocerebrosidase (GCase) enzyme activity in the brains of people with Parkinson’s disease. Results from a Phase 1b trial (NCT06732180) show that approximately three months of treatment with GT-02287 was safe and led to a robust reduction…
Recent Posts
- New exercise tips aim to help people with Parkinson’s stay active
- Getting approved for DBS surgery had me ‘feelin’ good as hell’
- First patient enrolled in new SER-252 trial for advanced Parkinson’s disease
- Painting a more accurate picture of being a caregiver
- Parkinson’s weight loss driven by burning fat instead of glucose